---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024996"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T16:52:23.130660+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty

## Summary
- Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
- Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.
- Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.
- Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.
- CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model.

## SEC filing metadata
- accession: 0001493152-25-024996
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024996
- JSON: https://secwatch.observer/filing/0001493152-25-024996.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024996.txt

## Key facts
- Governance Changes
  LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock with 2,700 shares, $1,000 stated value, no dividends, limited voting rights, liquidation preference senior to junior securities, convertible into common stock subject to beneficial ownership limitations (effective 2025-11-24).
  - Change: charter amendment
  - Effective: 2025-11-24
  source text: On November 24, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm
- M&A Transactions
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. completed an acquisition involving Orbit Capital Inc. for 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement (closed 2025-11-24).
  - Action: acquisition
  - Counterparty: Orbit Capital Inc.
  - Consideration: 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement
  - Closing: 2025-11-24
  source text: pursuant to a lease agreement. At the closing, the Company agreed to pay the following consideration (the “ Consideration ”) in exchange for the Shares: (i) issue to Seller 2,700 shares of the Company’s Series C Preferred Stock, $1,000 stated value per share (the “ Series C Preferred Stock ”) having such rights and preferences as set forth in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.